Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) will present new Phase 2 data on the triplet combination of monalizumab, cetuximab, and durvalumab for treating recurrent or metastatic head and neck squamous cell cancer at the ESMO Immuno-oncology Congress 2021, held virtually from December 8-11, 2021. This data focuses on first-line treatment in chemo-naïve patients. Additionally, an educational session will highlight ANKETTM, the company's NK cell engager platform. The oral presentation is scheduled for December 9, 2021.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced participation in the Evercore ISI 4th Annual HealthConX Virtual Conference on December 1, 2021. The fireside chat will take place from 5:20-5:40 pm CET (11:20-11:40 am ET). Innate Pharma focuses on developing therapeutic antibodies to enhance cancer treatment outcomes. The company has established significant partnerships with industry leaders, including Bristol-Myers Squibb and AstraZeneca, and is headquartered in Marseille, France, with a U.S. office in Rockville, MD.
Innate Pharma announced significant updates on its pipeline and financials for the first nine months of 2021. Key highlights include the advancement of monalizumab to Phase 3 after positive Phase 2 results in NSCLC, and promising pre-clinical data for ANKET™ targeting acute myeloid leukemia. The company's cash position stood at €141.8 million as of September 30, 2021, with revenues of €10.3 million for the same period, down from €33.6 million in 2020. The CEO emphasized a commitment to advancing its R&D strategy and collaborations, particularly with AstraZeneca.
Innate Pharma announced the presentation of pre-clinical data on IPH6101/SAR443579, a novel NK cell engager targeting CD123 in acute myeloid leukemia (AML), at the SITC Annual Meeting. The data demonstrated a favorable safety profile and potent antitumor activity, including efficacy against ADCC-resistant AML cells. These results support advancing IPH6101/SAR443579 into clinical trials. The collaboration with Sanofi enhances development opportunities, with the potential for significant milestone payments and royalties for Innate Pharma.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) will host a conference call on November 16, 2021, at 2 p.m. CET / 8 a.m. ET to update on business progress from Q3 2021. The call will feature CEO Mondher Mahjoubi and CMO Joyson Karakunnel. Investors can join via webcast or phone, with specific dial-in numbers provided. Innate Pharma focuses on oncology, leveraging therapeutic antibodies and Natural Killer cell biology, and has partnerships with major industry players like Bristol-Myers Squibb and AstraZeneca.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced its 2022 financial calendar, detailing key dates for financial statement publications. Significant dates include the release of 2021 financial statements on March 24, 2022, Q1 2022 revenue on May 10, 2022, and half-year financials on September 15, 2022. The Annual General Shareholders Meeting is scheduled for May 20, 2022. All reports will be issued before market open CET. Innate Pharma focuses on oncology, developing therapeutic antibodies that leverage the immune system for cancer treatment, with partnerships with notable industry leaders.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced the total number of shares and voting rights outstanding as of October 1, 2021. The company has 79,329,502 ordinary shares and a total of 80,087,342 theoretical voting rights. The release ensures compliance with French regulations set by the AMF. Innate Pharma is dedicated to oncology, focusing on immunotherapy through therapeutic antibodies, and maintains partnerships with notable biopharmaceutical firms. It is headquartered in Marseille, France, and has a US office in Rockville, MD.
On September 1, 2021, Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) reported its total number of outstanding shares and voting rights. The company has 79,294,402 ordinary shares and 6,784 Preferred Shares from 2016 and 7,581 from 2017. The total number of theoretical voting rights stands at 80,087,342, while exercisable voting rights amount to 80,068,767. This disclosure is in compliance with French regulations to ensure transparency in shareholding. Innate Pharma focuses on developing therapeutic antibodies for cancer treatment.
On September 17, 2021, Innate Pharma announced results from AstraZeneca's COAST Phase 2 trial presented at the ESMO Congress 2021. The interim analysis revealed that monalizumab combined with durvalumab significantly improved progression-free survival (PFS) and objective response rate (ORR) in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) following chemoradiation therapy. AstraZeneca plans to initiate a registrational study based on these promising results, highlighting the potential of monalizumab as a groundbreaking treatment targeting NKG2A receptors on tumor-infiltrating immune cells.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced promising results from the TELLOMAK trial, which showed a 35% overall global response rate for lacutamab in patients with mycosis fungoides. Financially, the company reported €15.7 million in revenue for H1 2021, a decline from €36.7 million in H1 2020, and a net loss of €23.7 million. Their cash position stands at €159.4 million.
Innate also launched new clinical trials for lacutamab and showcased advancements in their ANKET™ NK cell engager platform. Further data presentations are expected at upcoming conferences.
FAQ
What is the current stock price of Innate Pharma S.A. ADS (IPHA)?
What is the market cap of Innate Pharma S.A. ADS (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
